You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameApixaban
Accession NumberDB06605  (DB07828)
TypeSmall Molecule
GroupsApproved
DescriptionApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012.
Structure
Thumb
Synonyms
Apixabanum
BMS 562247-01
BMS-562247
BMS-562247-01
Eliquis
External Identifiers
  • BMS-562247
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EliquisFilm-coated tablet2.5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
Eliquistablet, film coated2.5 mg/1oralE.R. Squibb & Sons, L.L.C.2012-12-28Not applicableUs
EliquisFilm-coated tablet5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
Eliquistablet5.0 mgoralBristol Myers Squibb Canada2012-12-21Not applicableCanada
EliquisFilm-coated tablet2.5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet2.5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
Eliquistablet, film coated5 mg/1oralE.R. Squibb & Sons, L.L.C.2012-12-28Not applicableUs
EliquisFilm-coated tablet5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet2.5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet2.5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
Eliquistablet, film coated2.5 mg/1oralCardinal Health2012-12-28Not applicableUs
EliquisFilm-coated tablet2.5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet2.5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
Eliquistablet2.5 mgoralBristol Myers Squibb Canada2012-02-01Not applicableCanada
EliquisFilm-coated tablet5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisFilm-coated tablet5 mgOral useBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII3Z9Y7UWC1J
CAS number503612-47-3
WeightAverage: 459.4971
Monoisotopic: 459.190654313
Chemical FormulaC25H25N5O4
InChI KeyInChIKey=QNZCBYKSOIHPEH-UHFFFAOYSA-N
InChI
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
IUPAC Name
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide
SMILES
COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Phenylpyrazole
  • Methoxyaniline
  • Pyridinecarboxamide
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Piperidinone
  • Delta-lactam
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Pyrazole
  • Azole
  • Tertiary amine
  • Primary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationApixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
PharmacodynamicsApixaban acts by inhibiting coagulation, and thus prevents development of blood clots. As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban. The Rotachrom® Heparin chromogenic assay is not recommended for assessing the anticoagulant effect of apixaban.
Mechanism of actionApixaban acts by directly inhibiting, in a reversible manner, free and clot-bound factor Xa to inhibit coagulation.
Related Articles
AbsorptionApixaban is absorbed in the stomach and small intestine. For doses up to 10 mg, the absolute bioavailability is about 50%. For oral administration, absorption is not affected by the presence of food, and it takes about 3-4 hours to achieve maximum plasma concentrations. For large oral doses equal or greater than 25 mg, absorption is dissolution limited and bioavailability is decreased. Most of the absorption occurs in the distal small intestine and the ascending colon.
Volume of distribution

The steady state volume of distribution is 21 L.

Protein bindingApixaban is about 87% plasma protein bound.
Metabolism

Apixaban mainly undergoes o-demethylation and hydroxylation to metabolites. The major site of biotransformation is at the 3-oxopiperidinyl moiety. The main enzyme responsible for metabolism is CYP3A4/5 while CYP1A2, 2C8, 2C9, 2C19, and 2J2 are minor metabolic enzymes. There are no active metabolites and unchanged apixaban is the primary circulating entity.

Route of elimination25% of the administered dose is eliminated in the feces and urine. For elimination in the feces, it is excreted by the intestine and bile to the feces.
Half lifeIf administered orally, the half life is 12 hours (due to prolonged absorption). If administerd by I.V., the half-life is about 5 hours.
Clearance

About 27% of total apixaban is renally cleared.

ToxicityMajor bleeding events.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9329
Caco-2 permeable-0.5308
P-glycoprotein substrateSubstrate0.6144
P-glycoprotein inhibitor IInhibitor0.6804
P-glycoprotein inhibitor IIInhibitor0.594
Renal organic cation transporterNon-inhibitor0.5628
CYP450 2C9 substrateNon-substrate0.8528
CYP450 2D6 substrateNon-substrate0.811
CYP450 3A4 substrateSubstrate0.764
CYP450 1A2 substrateNon-inhibitor0.9271
CYP450 2C9 inhibitorInhibitor0.5555
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.5
CYP450 3A4 inhibitorInhibitor0.5
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6447
Ames testNon AMES toxic0.5062
CarcinogenicityNon-carcinogens0.8796
BiodegradationNot ready biodegradable0.9965
Rat acute toxicity2.3038 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8351
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Film-coated tabletOral use2.5 mg
Film-coated tabletOral use5 mg
Tabletoral2.5 mg
Tabletoral5.0 mg
Tablet, film coatedoral2.5 mg/1
Tablet, film coatedoral5 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2349330 No2009-09-292019-12-17Canada
CA2461202 No2011-07-122022-09-17Canada
US6413980 No1999-12-222019-12-22Us
US6967208 No2003-02-032023-02-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityAqueous solubility: 40-50 μg/ml in 0.9% saline solutionNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0679 mg/mLALOGPS
logP2.22ALOGPS
logP1.83ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)13.12ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.76 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity126.9 m3·mol-1ChemAxon
Polarizability49.62 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. [PubMed:21870978 ]
  2. de Souza Brito F, Lopes RD, Alexander JH: The safety and efficacy of apixaban : where do we stand in 2013? Expert Opin Drug Saf. 2013 Jul;12(4):559-67. doi: 10.1517/14740338.2013.799663. Epub 2013 May 10. [PubMed:23662974 ]
External Links
ATC CodesB01AF02
AHFS Codes
  • 20:12.04.14
PDB EntriesNot Available
FDA labelDownload (655 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Apixaban.
AbciximabApixaban may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Apixaban can be increased when it is combined with Abiraterone.
AceclofenacAceclofenac may increase the anticoagulant activities of Apixaban.
AcenocoumarolApixaban may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Apixaban can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Apixaban.
AdapaleneAdapalene may increase the anticoagulant activities of Apixaban.
AfatinibThe serum concentration of Apixaban can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Apixaban can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Apixaban can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Apixaban can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Apixaban can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Apixaban.
AllylestrenolThe therapeutic efficacy of Apixaban can be decreased when used in combination with Allylestrenol.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Apixaban.
AlprostadilAlprostadil may increase the anticoagulant activities of Apixaban.
AlteplaseAlteplase may increase the anticoagulant activities of Apixaban.
AltrenogestThe therapeutic efficacy of Apixaban can be decreased when used in combination with Altrenogest.
ALX-0081ALX-0081 may increase the anticoagulant activities of Apixaban.
AmantadineThe serum concentration of Apixaban can be increased when it is combined with Amantadine.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Apixaban.
Aminohippuric acidThe serum concentration of Apixaban can be increased when it is combined with Aminohippuric acid.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Apixaban.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Apixaban.
AmiodaroneThe serum concentration of Apixaban can be increased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Apixaban.
AmlodipineThe serum concentration of Apixaban can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Apixaban can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Apixaban can be increased when it is combined with Amsacrine.
AnagrelideAnagrelide may increase the anticoagulant activities of Apixaban.
AncrodApixaban may increase the anticoagulant activities of Ancrod.
AnistreplaseAnistreplase may increase the anticoagulant activities of Apixaban.
AntipyrineAntipyrine may increase the anticoagulant activities of Apixaban.
Antithrombin III humanApixaban may increase the anticoagulant activities of Antithrombin III human.
ApremilastApremilast may increase the anticoagulant activities of Apixaban.
AprepitantThe serum concentration of Apixaban can be increased when it is combined with Aprepitant.
AprotininThe therapeutic efficacy of Apixaban can be decreased when used in combination with Aprotinin.
ArdeparinApixaban may increase the anticoagulant activities of Ardeparin.
ArgatrobanApixaban may increase the anticoagulant activities of Argatroban.
ArmodafinilThe metabolism of Apixaban can be decreased when combined with Armodafinil.
AstaxanthinAstaxanthin may increase the anticoagulant activities of Apixaban.
AstemizoleThe serum concentration of Apixaban can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Apixaban can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Apixaban can be increased when it is combined with Atenolol.
AtomoxetineThe serum concentration of Apixaban can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Apixaban.
AzapropazoneAzapropazone may increase the anticoagulant activities of Apixaban.
AzelastineAzelastine may increase the anticoagulant activities of Apixaban.
AzithromycinThe serum concentration of Apixaban can be increased when it is combined with Azithromycin.
BalsalazideBalsalazide may increase the anticoagulant activities of Apixaban.
BatroxobinBatroxobin may increase the anticoagulant activities of Apixaban.
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Apixaban.
BecaplerminApixaban may increase the anticoagulant activities of Becaplermin.
BemiparinBemiparin may increase the anticoagulant activities of Apixaban.
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Apixaban.
BenzocaineThe serum concentration of Apixaban can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Apixaban can be increased when it is combined with Bepridil.
BeraprostBeraprost may increase the anticoagulant activities of Apixaban.
BexaroteneThe serum concentration of Apixaban can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Apixaban can be increased when it is combined with Biperiden.
BivalirudinApixaban may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Apixaban can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Apixaban can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Apixaban can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Apixaban can be increased when it is combined with Bosutinib.
BromfenacBromfenac may increase the anticoagulant activities of Apixaban.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Apixaban.
BuprenorphineThe serum concentration of Apixaban can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Apixaban can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Apixaban can be increased when it is combined with Cabazitaxel.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Apixaban.
CaffeineThe serum concentration of Apixaban can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Apixaban can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Apixaban can be increased when it is combined with Candesartan.
CangrelorCangrelor may increase the anticoagulant activities of Apixaban.
CapecitabineThe metabolism of Apixaban can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Apixaban can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Apixaban can be decreased when it is combined with Carbamazepine.
CarprofenCarprofen may increase the anticoagulant activities of Apixaban.
CarvedilolThe serum concentration of Apixaban can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Apixaban can be increased when it is combined with Caspofungin.
CastanospermineCastanospermine may increase the anticoagulant activities of Apixaban.
CelecoxibCelecoxib may increase the anticoagulant activities of Apixaban.
CeritinibThe serum concentration of Apixaban can be increased when it is combined with Ceritinib.
CertoparinApixaban may increase the anticoagulant activities of Certoparin.
ChloramphenicolThe metabolism of Apixaban can be decreased when combined with Chloramphenicol.
ChloroquineChloroquine may increase the anticoagulant activities of Apixaban.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Apixaban.
ChlorpromazineThe serum concentration of Apixaban can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Apixaban can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Apixaban can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Apixaban can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Apixaban can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Apixaban can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Apixaban can be increased when it is combined with Cilazapril.
CilostazolCilostazol may increase the anticoagulant activities of Apixaban.
CimetidineThe serum concentration of Apixaban can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Apixaban can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Apixaban.
CitalopramThe serum concentration of Apixaban can be increased when it is combined with Citalopram.
Citric AcidApixaban may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Apixaban can be increased when it is combined with Clarithromycin.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Apixaban.
ClemastineThe serum concentration of Apixaban can be increased when it is combined with Clemastine.
ClofazimineThe serum concentration of Apixaban can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Apixaban.
ClonixinClonixin may increase the anticoagulant activities of Apixaban.
ClopidogrelClopidogrel may increase the anticoagulant activities of Apixaban.
ClotrimazoleThe serum concentration of Apixaban can be increased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Apixaban can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Apixaban can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Apixaban can be increased when it is combined with Colforsin.
CollagenaseThe risk or severity of adverse effects can be increased when Apixaban is combined with Collagenase.
ConivaptanThe serum concentration of Apixaban can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Apixaban.
CrizotinibThe serum concentration of Apixaban can be increased when it is combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Apixaban.
CyclophosphamideThe risk or severity of adverse effects can be increased when Apixaban is combined with Cyclophosphamide.
CyclophosphamideThe serum concentration of Apixaban can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Apixaban can be increased when it is combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Apixaban can be decreased when it is combined with Cyproterone acetate.
D-LimoneneD-Limonene may increase the anticoagulant activities of Apixaban.
Dabigatran etexilateApixaban may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Apixaban can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Apixaban can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Apixaban can be increased when it is combined with Dactinomycin.
DalteparinApixaban may increase the anticoagulant activities of Dalteparin.
DanaparoidApixaban may increase the anticoagulant activities of Danaparoid.
DarunavirThe serum concentration of Apixaban can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Apixaban.
DaunorubicinThe serum concentration of Apixaban can be decreased when it is combined with Daunorubicin.
DeferasiroxThe risk or severity of adverse effects can be increased when Apixaban is combined with Deferasirox.
DeferasiroxThe serum concentration of Apixaban can be decreased when it is combined with Deferasirox.
DefibrotideDefibrotide may increase the anticoagulant activities of Apixaban.
DelavirdineThe serum concentration of Apixaban can be increased when it is combined with Delavirdine.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Apixaban.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Apixaban is combined with Deoxycholic Acid.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Apixaban.
DesirudinApixaban may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Apixaban can be increased when it is combined with Desloratadine.
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Apixaban.
DesogestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Desogestrel.
DexamethasoneThe serum concentration of Apixaban can be decreased when it is combined with Dexamethasone.
DextranApixaban may increase the anticoagulant activities of Dextran.
Dextran 40Apixaban may increase the anticoagulant activities of Dextran 40.
Dextran 70Apixaban may increase the anticoagulant activities of Dextran 70.
Dextran 75Apixaban may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Apixaban can be increased when it is combined with Dextromethorphan.
DiclofenacDiclofenac may increase the anticoagulant activities of Apixaban.
DicoumarolApixaban may increase the anticoagulant activities of Dicoumarol.
DienestrolDienestrol may decrease the anticoagulant activities of Apixaban.
DienogestThe therapeutic efficacy of Apixaban can be decreased when used in combination with Dienogest.
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Apixaban.
DiflunisalDiflunisal may increase the anticoagulant activities of Apixaban.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Apixaban.
DigoxinThe serum concentration of Apixaban can be decreased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Apixaban can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Apixaban can be increased when it is combined with Diltiazem.
DipyridamoleDipyridamole may increase the anticoagulant activities of Apixaban.
DitazoleDitazole may increase the anticoagulant activities of Apixaban.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Apixaban.
DoxazosinThe serum concentration of Apixaban can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Apixaban.
DoxorubicinThe serum concentration of Apixaban can be decreased when it is combined with Doxorubicin.
DoxycyclineThe serum concentration of Apixaban can be increased when it is combined with Doxycycline.
DronabinolThe serum concentration of Apixaban can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Apixaban can be increased when it is combined with Dronedarone.
DrospirenoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Drospirenone.
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Apixaban.
DroxicamDroxicam may increase the anticoagulant activities of Apixaban.
DydrogesteroneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Dydrogesterone.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Apixaban.
Edetic AcidApixaban may increase the anticoagulant activities of Edetic Acid.
EdoxabanApixaban may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Apixaban can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Apixaban can be increased when it is combined with Elbasvir.
EltrombopagThe serum concentration of Apixaban can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Apixaban can be increased when it is combined with Enalapril.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Apixaban.
EnoxaparinApixaban may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Apixaban can be decreased when it is combined with Enzalutamide.
EpinastineEpinastine may increase the anticoagulant activities of Apixaban.
EpirizoleEpirizole may increase the anticoagulant activities of Apixaban.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Apixaban.
EpoprostenolThe risk or severity of adverse effects can be increased when Apixaban is combined with Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Apixaban.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Apixaban.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Apixaban.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Apixaban.
ErythromycinThe serum concentration of Apixaban can be increased when it is combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Apixaban can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Apixaban.
EsomeprazoleThe metabolism of Apixaban can be decreased when combined with Esomeprazole.
EstradiolEstradiol may decrease the anticoagulant activities of Apixaban.
EstramustineThe serum concentration of Apixaban can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Apixaban can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Apixaban can be decreased when it is combined with Estrone.
EtanerceptEtanercept may increase the anticoagulant activities of Apixaban.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Apixaban.
Ethyl biscoumacetateApixaban may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacEtodolac may increase the anticoagulant activities of Apixaban.
EtofenamateEtofenamate may increase the anticoagulant activities of Apixaban.
EtonogestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Etonogestrel.
EtoposideThe serum concentration of Apixaban can be increased when it is combined with Etoposide.
EtoricoxibEtoricoxib may increase the anticoagulant activities of Apixaban.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Apixaban.
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Apixaban.
exisulindexisulind may increase the anticoagulant activities of Apixaban.
FelodipineThe serum concentration of Apixaban can be increased when it is combined with Felodipine.
FenbufenFenbufen may increase the anticoagulant activities of Apixaban.
FenoprofenFenoprofen may increase the anticoagulant activities of Apixaban.
FentanylThe serum concentration of Apixaban can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Apixaban can be increased when it is combined with Fexofenadine.
FibrinolysinFibrinolysin may increase the anticoagulant activities of Apixaban.
FidaxomicinThe serum concentration of Apixaban can be increased when it is combined with Fidaxomicin.
FloctafenineFloctafenine may increase the anticoagulant activities of Apixaban.
FloxuridineThe metabolism of Apixaban can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Apixaban can be increased when it is combined with Fluconazole.
FlunixinFlunixin may increase the anticoagulant activities of Apixaban.
FluorouracilThe metabolism of Apixaban can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Apixaban can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Apixaban can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Apixaban can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Apixaban can be increased when it is combined with Flurazepam.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Apixaban.
FluvastatinThe metabolism of Apixaban can be decreased when combined with Fluvastatin.
FluvoxamineThe serum concentration of Apixaban can be increased when it is combined with Fluvoxamine.
Fondaparinux sodiumApixaban may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe serum concentration of Apixaban can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Apixaban can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Apixaban can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Apixaban can be increased when it is combined with Fusidic Acid.
GarlicThe serum concentration of Apixaban can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Apixaban can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Apixaban can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Apixaban can be increased when it is combined with Genistein.
GestodeneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Gestodene.
GlyburideThe serum concentration of Apixaban can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Apixaban can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Apixaban can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Apixaban can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Apixaban can be increased when it is combined with Haloperidol.
HeminHemin may increase the anticoagulant activities of Apixaban.
HeparinApixaban may increase the anticoagulant activities of Heparin.
HexestrolHexestrol may decrease the anticoagulant activities of Apixaban.
HirulogApixaban may increase the anticoagulant activities of Hirulog.
HMPL-004HMPL-004 may increase the anticoagulant activities of Apixaban.
HydrocortisoneThe serum concentration of Apixaban can be increased when it is combined with Hydrocortisone.
Hydroxyprogesterone caproateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Hydroxyprogesterone caproate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Apixaban.
IbudilastIbudilast may increase the anticoagulant activities of Apixaban.
IbuprofenIbuprofen may increase the anticoagulant activities of Apixaban.
IbuproxamIbuproxam may increase the anticoagulant activities of Apixaban.
IcatibantIcatibant may increase the anticoagulant activities of Apixaban.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Apixaban.
IdelalisibThe serum concentration of Apixaban can be increased when it is combined with Idelalisib.
IfenprodilIfenprodil may increase the anticoagulant activities of Apixaban.
IloprostIloprost may increase the anticoagulant activities of Apixaban.
IloprostThe risk or severity of adverse effects can be increased when Apixaban is combined with Iloprost.
ImatinibThe serum concentration of Apixaban can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Apixaban.
IndinavirThe serum concentration of Apixaban can be increased when it is combined with Indinavir.
IndomethacinIndomethacin may increase the anticoagulant activities of Apixaban.
IndoprofenIndoprofen may increase the anticoagulant activities of Apixaban.
IrbesartanThe metabolism of Apixaban can be decreased when combined with Irbesartan.
IsavuconazoniumThe serum concentration of Apixaban can be increased when it is combined with Isavuconazonium.
IsoniazidThe metabolism of Apixaban can be decreased when combined with Isoniazid.
IsoxicamIsoxicam may increase the anticoagulant activities of Apixaban.
IsradipineThe serum concentration of Apixaban can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Apixaban can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Apixaban can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Apixaban can be increased when it is combined with Ivermectin.
KebuzoneKebuzone may increase the anticoagulant activities of Apixaban.
KetamineThe serum concentration of Apixaban can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Apixaban can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may increase the anticoagulant activities of Apixaban.
KetorolacKetorolac may increase the anticoagulant activities of Apixaban.
LansoprazoleThe serum concentration of Apixaban can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Apixaban can be increased when it is combined with Lapatinib.
LeflunomideLeflunomide may increase the anticoagulant activities of Apixaban.
LepirudinApixaban may increase the anticoagulant activities of Lepirudin.
LevofloxacinThe serum concentration of Apixaban can be increased when it is combined with Levofloxacin.
LevonorgestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Levonorgestrel.
LevothyroxineThe serum concentration of Apixaban can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Apixaban can be increased when it is combined with Lidocaine.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Apixaban.
LiothyronineThe serum concentration of Apixaban can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Apixaban can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Apixaban can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Apixaban can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Apixaban can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Apixaban can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Apixaban can be increased when it is combined with Loratadine.
LornoxicamLornoxicam may increase the anticoagulant activities of Apixaban.
LosartanThe serum concentration of Apixaban can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Apixaban can be increased when it is combined with Lovastatin.
LoxoprofenLoxoprofen may increase the anticoagulant activities of Apixaban.
LuliconazoleThe serum concentration of Apixaban can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Apixaban can be decreased when it is combined with Lumacaftor.
LumiracoxibLumiracoxib may increase the anticoagulant activities of Apixaban.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Apixaban.
MaprotilineThe serum concentration of Apixaban can be increased when it is combined with Maprotiline.
MasoprocolMasoprocol may increase the anticoagulant activities of Apixaban.
MebendazoleThe serum concentration of Apixaban can be increased when it is combined with Mebendazole.
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Apixaban.
MedrogestoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medrogestone.
Medroxyprogesterone acetateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Apixaban.
MefloquineThe serum concentration of Apixaban can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Apixaban can be increased when it is combined with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Apixaban.
MeprobamateThe serum concentration of Apixaban can be increased when it is combined with Meprobamate.
MesalazineMesalazine may increase the anticoagulant activities of Apixaban.
MestranolMestranol may decrease the anticoagulant activities of Apixaban.
MetamizoleMetamizole may increase the anticoagulant activities of Apixaban.
MethadoneThe serum concentration of Apixaban can be increased when it is combined with Methadone.
MetoprololThe serum concentration of Apixaban can be increased when it is combined with Metoprolol.
MexiletineThe metabolism of Apixaban can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Apixaban can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Apixaban can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Apixaban.
MidazolamThe serum concentration of Apixaban can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Apixaban can be increased when it is combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Apixaban.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Apixaban.
MitomycinThe serum concentration of Apixaban can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Apixaban can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Apixaban can be decreased when it is combined with Mitoxantrone.
MoclobemideThe metabolism of Apixaban can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Apixaban can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Apixaban can be increased when it is combined with Morphine.
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Apixaban.
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Apixaban.
NabumetoneNabumetone may increase the anticoagulant activities of Apixaban.
NadroparinApixaban may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Apixaban can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may increase the anticoagulant activities of Apixaban.
NaltrexoneThe serum concentration of Apixaban can be increased when it is combined with Naltrexone.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Apixaban.
NaringeninThe serum concentration of Apixaban can be increased when it is combined with Naringenin.
NCX 4016NCX 4016 may increase the anticoagulant activities of Apixaban.
NefazodoneThe serum concentration of Apixaban can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Apixaban can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Apixaban can be increased when it is combined with Neostigmine.
NepafenacNepafenac may increase the anticoagulant activities of Apixaban.
NetupitantThe serum concentration of Apixaban can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Apixaban can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Apixaban can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Apixaban can be decreased when it is combined with Nifedipine.
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Apixaban.
NilotinibThe serum concentration of Apixaban can be increased when it is combined with Nilotinib.
NimesulideNimesulide may increase the anticoagulant activities of Apixaban.
NintedanibThe risk or severity of adverse effects can be increased when Apixaban is combined with Nintedanib.
NisoldipineThe serum concentration of Apixaban can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Apixaban can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Apixaban can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Apixaban can be decreased when it is combined with Norethisterone.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Apixaban.
ObinutuzumabThe risk or severity of adverse effects can be increased when Apixaban is combined with Obinutuzumab.
OlaparibThe serum concentration of Apixaban can be increased when it is combined with Olaparib.
OlopatadineOlopatadine may increase the anticoagulant activities of Apixaban.
OlsalazineOlsalazine may increase the anticoagulant activities of Apixaban.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Apixaban is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Apixaban.
OmeprazoleThe serum concentration of Apixaban can be increased when it is combined with Omeprazole.
OrgoteinOrgotein may increase the anticoagulant activities of Apixaban.
OsimertinibThe serum concentration of Apixaban can be increased when it is combined with Osimertinib.
OtamixabanApixaban may increase the anticoagulant activities of Otamixaban.
OxaprozinOxaprozin may increase the anticoagulant activities of Apixaban.
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Apixaban.
P-NitrophenolThe serum concentration of Apixaban can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Apixaban can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Apixaban can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Apixaban can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Apixaban can be increased when it is combined with Pantoprazole.
ParecoxibParecoxib may increase the anticoagulant activities of Apixaban.
ParnaparinParnaparin may increase the anticoagulant activities of Apixaban.
ParoxetineThe serum concentration of Apixaban can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Apixaban can be increased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe serum concentration of Apixaban can be decreased when it is combined with Pentobarbital.
Pentosan PolysulfateApixaban may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Apixaban.
PerindoprilThe serum concentration of Apixaban can be increased when it is combined with Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Apixaban is combined with Pethidine.
PhenindioneApixaban may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Apixaban can be decreased when it is combined with Phenobarbital.
PhenprocoumonApixaban may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Apixaban.
PhenytoinThe serum concentration of Apixaban can be decreased when it is combined with Phenytoin.
PimecrolimusPimecrolimus may increase the anticoagulant activities of Apixaban.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Apixaban.
PioglitazoneThe metabolism of Apixaban can be decreased when combined with Pioglitazone.
PirfenidonePirfenidone may increase the anticoagulant activities of Apixaban.
PiroxicamPiroxicam may increase the anticoagulant activities of Apixaban.
PlasminPlasmin may increase the anticoagulant activities of Apixaban.
Platelet Activating FactorThe serum concentration of Apixaban can be decreased when it is combined with Platelet Activating Factor.
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Apixaban.
PonatinibThe serum concentration of Apixaban can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Apixaban can be increased when it is combined with Posaconazole.
PrasugrelPrasugrel may increase the anticoagulant activities of Apixaban.
PravastatinThe serum concentration of Apixaban can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Apixaban can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Apixaban can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Apixaban can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Apixaban can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Apixaban can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Apixaban can be increased when it is combined with Promethazine.
PropacetamolPropacetamol may increase the anticoagulant activities of Apixaban.
PropafenoneThe serum concentration of Apixaban can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Apixaban can be increased when it is combined with Propranolol.
Protein CApixaban may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeApixaban may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Apixaban.
PTC299PTC299 may increase the anticoagulant activities of Apixaban.
PyrimethamineThe metabolism of Apixaban can be decreased when combined with Pyrimethamine.
QuercetinThe serum concentration of Apixaban can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Apixaban can be increased when it is combined with Quinacrine.
QuinestrolQuinestrol may decrease the anticoagulant activities of Apixaban.
QuinidineThe serum concentration of Apixaban can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Apixaban can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Apixaban can be decreased when combined with Rabeprazole.
RanitidineThe serum concentration of Apixaban can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Apixaban can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Apixaban can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Apixaban can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Apixaban can be decreased when it is combined with Reserpine.
ResveratrolResveratrol may increase the anticoagulant activities of Apixaban.
ReteplaseReteplase may increase the anticoagulant activities of Apixaban.
ReviparinApixaban may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Apixaban.
RifabutinThe serum concentration of Apixaban can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Apixaban can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Apixaban can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Apixaban can be increased when it is combined with Rilpivirine.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Apixaban.
RitonavirThe serum concentration of Apixaban can be increased when it is combined with Ritonavir.
RivaroxabanApixaban may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the anticoagulant activities of Apixaban.
RolapitantThe serum concentration of Apixaban can be increased when it is combined with Rolapitant.
RopiniroleThe metabolism of Apixaban can be decreased when combined with Ropinirole.
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Apixaban.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Apixaban.
SalicylamideSalicylamide may increase the anticoagulant activities of Apixaban.
Salicylic acidSalicylic acid may increase the anticoagulant activities of Apixaban.
SalsalateSalsalate may increase the anticoagulant activities of Apixaban.
SaquinavirThe serum concentration of Apixaban can be increased when it is combined with Saquinavir.
SCH-530348SCH-530348 may increase the anticoagulant activities of Apixaban.
ScopolamineThe serum concentration of Apixaban can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Apixaban can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Apixaban can be increased when it is combined with Selegiline.
SelexipagSelexipag may increase the anticoagulant activities of Apixaban.
SeratrodastSeratrodast may increase the anticoagulant activities of Apixaban.
SertralineThe serum concentration of Apixaban can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the anticoagulant activities of Apixaban.
SildenafilThe serum concentration of Apixaban can be increased when it is combined with Sildenafil.
SiltuximabThe serum concentration of Apixaban can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Apixaban can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Apixaban.
SirolimusThe serum concentration of Apixaban can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Apixaban can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Apixaban can be increased when it is combined with Spironolactone.
SRT501SRT501 may increase the anticoagulant activities of Apixaban.
St. John's WortThe metabolism of Apixaban can be increased when combined with St. John's Wort.
StaurosporineThe serum concentration of Apixaban can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Apixaban can be increased when it is combined with Stiripentol.
StreptokinaseStreptokinase may increase the anticoagulant activities of Apixaban.
StreptozocinThe serum concentration of Apixaban can be decreased when it is combined with Streptozocin.
SugammadexSugammadex may increase the anticoagulant activities of Apixaban.
SulfadiazineThe metabolism of Apixaban can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Apixaban can be decreased when combined with Sulfamethoxazole.
SulfasalazineSulfasalazine may increase the anticoagulant activities of Apixaban.
SulfinpyrazoneThe serum concentration of Apixaban can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe serum concentration of Apixaban can be increased when it is combined with Sulfisoxazole.
SulindacSulindac may increase the anticoagulant activities of Apixaban.
SulodexideApixaban may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Apixaban can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Apixaban can be increased when it is combined with Sunitinib.
SuprofenSuprofen may increase the anticoagulant activities of Apixaban.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Apixaban.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Apixaban.
TacrineThe serum concentration of Apixaban can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Apixaban.
TacrolimusThe serum concentration of Apixaban can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Apixaban can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Apixaban can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Apixaban can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Apixaban can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Apixaban can be increased when it is combined with Telmisartan.
TemsirolimusThe risk or severity of adverse effects can be increased when Apixaban is combined with Temsirolimus.
TemsirolimusThe serum concentration of Apixaban can be increased when it is combined with Temsirolimus.
TenecteplaseTenecteplase may increase the anticoagulant activities of Apixaban.
TenofovirThe metabolism of Apixaban can be decreased when combined with Tenofovir.
TenoxicamTenoxicam may increase the anticoagulant activities of Apixaban.
TepoxalinTepoxalin may increase the anticoagulant activities of Apixaban.
TerazosinThe serum concentration of Apixaban can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Apixaban can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Apixaban can be decreased when it is combined with Teriflunomide.
TesmilifeneTesmilifene may increase the anticoagulant activities of Apixaban.
TestosteroneThe serum concentration of Apixaban can be increased when it is combined with Testosterone.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Apixaban.
TheophyllineThe metabolism of Apixaban can be decreased when combined with Theophylline.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Apixaban.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Apixaban.
TiboloneTibolone may increase the anticoagulant activities of Apixaban.
TicagrelorTicagrelor may increase the anticoagulant activities of Apixaban.
TiclopidineThe serum concentration of Apixaban can be increased when it is combined with Ticlopidine.
TinzaparinTinzaparin may increase the anticoagulant activities of Apixaban.
TipranavirThe serum concentration of Apixaban can be decreased when it is combined with Tipranavir.
TirofibanTirofiban may increase the anticoagulant activities of Apixaban.
TocilizumabThe serum concentration of Apixaban can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Apixaban can be decreased when combined with Tolbutamide.
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Apixaban.
TolmetinTolmetin may increase the anticoagulant activities of Apixaban.
TolvaptanThe serum concentration of Apixaban can be increased when it is combined with Tolvaptan.
TopiramateThe metabolism of Apixaban can be decreased when combined with Topiramate.
TositumomabThe risk or severity of adverse effects can be increased when Apixaban is combined with Tositumomab.
TranilastTranilast may increase the anticoagulant activities of Apixaban.
TranylcypromineThe metabolism of Apixaban can be decreased when combined with Tranylcypromine.
TrapidilTrapidil may increase the anticoagulant activities of Apixaban.
TrazodoneThe serum concentration of Apixaban can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the anticoagulant activities of Apixaban.
TreprostinilThe risk or severity of adverse effects can be increased when Apixaban is combined with Treprostinil.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Apixaban.
TrifluoperazineThe serum concentration of Apixaban can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Apixaban can be increased when it is combined with Triflupromazine.
TriflusalTriflusal may increase the anticoagulant activities of Apixaban.
TrimethoprimThe serum concentration of Apixaban can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Apixaban.
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Apixaban.
TroleandomycinThe serum concentration of Apixaban can be increased when it is combined with Troleandomycin.
UrokinaseUrokinase may increase the anticoagulant activities of Apixaban.
ValdecoxibValdecoxib may increase the anticoagulant activities of Apixaban.
Valproic AcidThe metabolism of Apixaban can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Apixaban can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Apixaban can be increased when it is combined with Vemurafenib.
VenlafaxineThe serum concentration of Apixaban can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Apixaban can be increased when it is combined with Verapamil.
VinblastineThe serum concentration of Apixaban can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Apixaban can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Apixaban can be increased when it is combined with Vinorelbine.
Vitamin EVitamin E may increase the anticoagulant activities of Apixaban.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Apixaban.
VoriconazoleThe serum concentration of Apixaban can be increased when it is combined with Voriconazole.
WarfarinApixaban may increase the anticoagulant activities of Warfarin.
XimelagatranApixaban may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Apixaban can be decreased when combined with Zafirlukast.
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Apixaban.
ZeranolZeranol may decrease the anticoagulant activities of Apixaban.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Apixaban.
ZileutonZileuton may increase the anticoagulant activities of Apixaban.
ZimelidineThe serum concentration of Apixaban can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of Apixaban can be increased when it is combined with Ziprasidone.
ZomepiracZomepirac may increase the anticoagulant activities of Apixaban.
Food Interactions
  • Alfalfa, Anise, Bilberry may increase the adverse effects of apixaban.
  • Grapefruit juice may increase apixaban serum concentration.
  • St. John's wort will likely decrease apixaban serum concentration. Avoid combination if possible.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name:
F10
Uniprot ID:
P00742
Molecular Weight:
54731.255 Da
References
  1. Spyropoulos AC: Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs. 2007 Apr;16(4):431-40. [PubMed:17371192 ]
  2. Harenberg J, Wehling M: Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023. [PubMed:18393142 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ: In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Epub 2009 Nov 25. [PubMed:19940026 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. de Souza Brito F, Lopes RD, Alexander JH: The safety and efficacy of apixaban : where do we stand in 2013? Expert Opin Drug Saf. 2013 Jul;12(4):559-67. doi: 10.1517/14740338.2013.799663. Epub 2013 May 10. [PubMed:23662974 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:40 / Updated on September 27, 2016 02:27